Pfizer Inc. to Support Indiana University Informatics Search for Pathways to New Medical Discoveries
Published: Sep 22, 2010
IU Bloomington School of Informatics and Computing Professor David Wild will use large-scale semantic Web-based data mining and network methods to seek to uncover previously undiscovered historical links between chemical compounds, drugs, biological pathways, targets, genes and diseases.
David Wild will use a grant from Pfizer and large-scale data-mining techniques to try and uncover historical links between chemical compounds, drugs, biological pathways, genes and diseases that could facilitate new drug and treatment therapies.
Pfizer has awarded Wild $140,000 to conduct the chemogenomics study and to facilitate research relating to the discovery of new therapies and treatments.
"This research is significant because it will for the first time provide a large-scale public chemogenomics resource with integrated data mining tools," Wild said. "Biomedical researchers will be able to use this to seek to find new important biological relationships and to help discover new drugs."
The field of chemogenomics, often described in a wider sense as "systems chemical biology," is rapidly emerging as a way of helping discover new disease therapies and uncovering new uses for existing drugs.
Wild's lab has already created Chem2Bio2RDF, a prototype semantic resource Web-based program that integrates vast quantities of public chemical and biological data on compounds, drugs, genes, pathways, diseases, side-effects and scholarly publications, along with some initial tools for mining the data.
That resource and its associated tools already show promise for important potential biomedical applications, including predicting off-target and multi-target interactions of drugs and chemical compounds, finding potential applications of existing drugs to new therapeutic areas, and discovery of currently unknown desirable biological effects of existing chemical compounds.
"Professor Wild and his research team are developing innovative solutions to some very complex data mining problems in associating chemical structure to biological activities across numerous databases relevant to drug discovery," said Jeff Howe, senior director in Pfizer's Computational Sciences Center of Emphasis. "We are pleased to support his leading-edge research on semantic Web-based data mining for chemogenomics and systems chemical biology."
Peter Luke, senior director of R&D Business Development at Pfizer, said the support was an example of a growing willingness to create opportunities for collaborations between industry and academia.
"As pre-competitive research through open innovation with academic institutions becomes even more important within the pharmaceutical Industry, we are pleased to fund this research, which is yet another example of partnering with institutions to facilitate novel science programs," Luke said.
About the Indiana University School of Informatics
Founded in 2000 as the first school of its kind in the United States, the Indiana University School of Informatics is dedicated to research and teaching across a broad range of computing and information technology, with emphases on science, applications and societal implications. The school includes the School of Informatics at IUPUI and the School of Informatics and Computing at Bloomington, where programs include computer science and informatics. The school administers a variety of bachelor and masters degree programs in computer science and informatics, as well as Ph.D. programs in computer science, and the first-ever Ph.D. in informatics. The school is dedicated to excellence in education and research, to partnerships that bolster economic development and entrepreneurship, and to increasing opportunities for women and underrepresented minorities in computing and technology. For more information, visit http://www.soic.indiana.edu.
To speak with Wild, please contact Steve Chaplin, University Communications, at 812-856-1896 or firstname.lastname@example.org.